(Q46255077)

English

Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

author name string

Jason M Foster

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

Zoran Gatalica

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

Stan Lilleberg

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

Gleb Haynatzki

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

Brian W Loggie

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

publication date

8 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

Annals of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

16

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

152-158

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

A review of peritoneal mesothelioma at the Washington Cancer Institute

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Epidermal growth factor receptor mutation testing in the care of lung cancer patients

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Mutation detection using a novel plant endonuclease

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Purification, cloning, and characterization of the CEL I nuclease

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Quantitative prognostic indicators of peritoneal dissemination of gastric cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Quantitative prognostic indices in peritoneal carcinomatosis

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Mechanisms in the Pathogenesis of Asbestosis and Silicosis

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Akt expression may predict favorable prognosis in cholangiocarcinoma.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

1 reference

https://api.crossref.org/works/10.1245%2FS10434-008-0206-6

21 January 2018

Identifiers

10.1245/S10434-008-0206-6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/18998063

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46255077&oldid=2207746048"